Press release
Emerging Tech Quartet - PRSO, LXRX, PRTG, RNAZ - Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics
A new wave of innovation is taking hold across the biotech and tech sectors, with four high-impact companies-Peraso Inc. (NASDAQ: PRSO), Lexicon Pharmaceuticals (NASDAQ: LXRX), Portage Biotech (NASDAQ: PRTG), and TransCode Therapeutics (NASDAQ: RNAZ)-each making strategic advances in their respective arenas: military-grade wireless, obesity treatment, cancer immunotherapy, and RNA-based oncology solutions. These breakthroughs represent critical inflection points for investors eyeing cutting-edge solutions backed by scientific validation, regulatory momentum, and untapped market potential.Peraso Inc. (NASDAQ: PRSO) , a leader in millimeter wave (mmWave) technology, is targeting and advancing into the military wireless space-long dominated by legacy defense firms. Leveraging its patented 60GHz mmWave solutions, Peraso aims to deliver secure, high-speed communications across UAVs, radar systems, and battlefield networks.
The company holds key IP, including patents addressing interference management and beamforming antenna systems, giving it a tactical edge in next-gen defense communications. As global defense systems shift to next-gen wireless, demand for cost-effective, license-free mmWave connectivity is surging-positioning Peraso as a frontrunner ahead of larger, slower-moving competitors.
"Peraso's mmWave platform offers a strong alternative to traditional RF systems," said an industry analyst. CEO Ron Glibbery recently discussed the company's strategy on The Street Reports Podcast [https://thestreetreports.com/peraso-incs-ceo-ron-glibbery-discusses-the-future-of-60-ghz-mmwave-5g-ai-driven-connectivity-and-military-applications-on-the-street-podcast-listen-now/] , listen now.
With growing defense budgets and emphasis on unlicensed, high-throughput tech, Peraso is building long-term value in a rapidly evolving market-emerging as a high-potential wireless stock aligned with modern battlefield needs.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has signed a global licensing deal with Novo Nordisk for its oral obesity drug candidate LX9851 , potentially worth up to $1 billion, including $75 million in upfront and near-term milestones. LX9851, which targets the ACSL5 enzyme, has shown strong preclinical results, especially when paired with semaglutide. Novo Nordisk will handle development and commercialization, while Lexicon is eligible for tiered royalties on sales.
Portage Biotech (NASDAQ: PRTG) reported breakthrough preclinical results for PORT-7 , showing over 90% tumor reduction in mesothelioma models when combined with an anti-PD-1 antibody. Presented at the 2025 ELCC in Paris, the data marks the first evidence of selective A2B inhibition efficacy in this cancer type. Portage plans to launch a first-in-human trial and is also advancing PORT-6 , a selective A2A inhibitor, with plans to combine both agents in the ADPORT-601 trial for enhanced immunotherapy impact.
TransCode Therapeutics (NASDAQ: RNAZ) has dosed the first patient in Cohort 4 of its Phase 1 trial for TTX-MC138 , an RNA therapy targeting metastatic cancer via microRNA-10b inhibition. Ten patients have been treated so far with no major safety issues. The latest dose is 50% higher than in the previous cohort, with more patients being evaluated for enrollment.
From Peraso's patent-backed 60GHz mmWave wireless tech gaining traction in military communications, to Lexicon's $1B obesity licensing deal with Novo Nordisk, Portage's novel adenosine pathway immunotherapy in mesothelioma, and TransCode's advancement of RNA cancer therapeutics with no safety red flags-these emerging players are reshaping their sectors with disruptive potential. As investor interest shifts toward science-backed innovation and defense-grade infrastructure, PRSO, LXRX, PRTG, and RNAZ are fast becoming tickers to watch in 2025's next-generation growth landscape.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=emerging-tech-quartetprso-lxrx-prtg-rnaz-drive-breakthroughs-across-defense-obesity-oncology-and-rna-therapeutics]
Country: United States
Website: http://www.thestreetreports.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emerging Tech Quartet - PRSO, LXRX, PRTG, RNAZ - Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics here
News-ID: 3945841 • Views: …
More Releases from ABNewswire
ARHT Home Solutions - Derwood's Premier Choice for Reliable Chimney Repair and M …
ARHT Home Solutions provides expert chimney repair and maintenance in Derwood, Maryland. Skilled technicians restore safety, durability, and efficiency through detailed inspections and high-quality workmanship. From minor fixes to complete restoration, their chimney repair services ensure lasting performance for homes seeking trusted local solutions.
A chimney plays a vital role in keeping a home safe, ventilated, and comfortable. Over time, exposure to heat, moisture, and outdoor elements can weaken brickwork, mortar,…
TWFG Khan Insurance Services Addresses Growing Demand for Maritime General Liabi …
TWFG Khan Insurance Services responds to growing maritime insurance demands in Texas by providing specialized coverage for vessel operators, marine contractors, and port businesses facing complex liability exposures along the Gulf Coast.
The Texas shipping industry faces mounting pressure to secure comprehensive insurance protection as maritime operations expand across the Gulf Coast. TWFG Khan Insurance Services [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-8-27-twfg-khan-insurance-services-launches-comprehensive-general-liability-insurance-in-houston-tx-program-for-high-risk-industries-amid-growing-market-demand] has responded to this trend by strengthening its position as a specialized provider for…
Wirks Moving & Storage Donates Moving Services to Local Disaster Relief, Leading …
Wirks Moving and Storage - Atlanta Movers launched disaster relief services, providing free moving assistance to families affected by severe weather, demonstrating industry leadership in community support.
Wirks Moving and Storage - Atlanta Movers has launched a comprehensive disaster relief initiative, providing free moving services to families affected by recent natural disasters. The Atlanta-based company's charitable efforts highlight growing trends of corporate social responsibility within the relocation industry.
Immediate Response to Community…
Marietta Movers Achieve Zero-Incident Safety Record Across 20,000+ Relocations i …
Wirks Moving and Storage - Marietta Movers achieves zero safety incidents across 20,000+ Metro Atlanta relocations, setting new industry standards for professional moving services in Georgia.
The professional relocation industry reaches a significant milestone as Wirks Moving and Storage - Marietta Movers [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-8-14-wirks-moving-and-storage-transforms-search-for-moving-companies-near-me-with-enhanced-247-services-across-the-atlanta-metropolitan-area] documents zero safety incidents across more than 20,000 completed relocations throughout the Metro Atlanta region. This achievement establishes new safety benchmarks for moving companies [https://maps.app.goo.gl/bw9NSpAaDtp93afL7#moving-companies] operating in Georgia's…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
